Free Trial
NASDAQ:CYCN

Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis

Cyclerion Therapeutics logo
$1.89 -0.20 (-9.38%)
(As of 02:45 PM ET)

About Cyclerion Therapeutics Stock (NASDAQ:CYCN)

Key Stats

Today's Range
$1.55
$2.01
50-Day Range
$1.76
$3.16
52-Week Range
$1.55
$5.25
Volume
449,620 shs
Average Volume
69,484 shs
Market Capitalization
$5.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Cyclerion Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
20th Percentile Overall Score

CYCN MarketRank™: 

Cyclerion Therapeutics scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Cyclerion Therapeutics.

  • Price to Book Value per Share Ratio

    Cyclerion Therapeutics has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.69% of the float of Cyclerion Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclerion Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclerion Therapeutics has recently increased by 20.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cyclerion Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cyclerion Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.69% of the float of Cyclerion Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclerion Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclerion Therapeutics has recently increased by 20.00%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Cyclerion Therapeutics this week, compared to 0 articles on an average week.
  • Search Interest

    8 people have searched for CYCN on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added Cyclerion Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cyclerion Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    36.10% of the stock of Cyclerion Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    75.62% of the stock of Cyclerion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cyclerion Therapeutics' insider trading history.
Receive CYCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYCN Stock News Headlines

New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
Cyclerion Therapeutics Inc Ordinary Shares CYCN
Cyclerion Therapeutics Inc (CYCN)
See More Headlines

CYCN Stock Analysis - Frequently Asked Questions

Cyclerion Therapeutics' stock was trading at $3.35 at the start of the year. Since then, CYCN stock has decreased by 45.1% and is now trading at $1.84.
View the best growth stocks for 2024 here
.

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) issued its quarterly earnings data on Tuesday, November, 9th. The company reported ($5.20) EPS for the quarter, topping the consensus estimate of ($7.00) by $1.80. The company had revenue of $0.35 million for the quarter, compared to analyst estimates of $3 million.

Shares of Cyclerion Therapeutics reverse split on the morning of Tuesday, May 16th 2023. The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclerion Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), General Electric (GE), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
11/09/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CYCN
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Net Income
$-5,260,000.00
Pretax Margin
-2,722.68%

Debt

Sales & Book Value

Annual Sales
$1.62 million
Book Value
$4.62 per share

Miscellaneous

Free Float
1,732,000
Market Cap
$5.66 million
Optionable
No Data
Beta
1.93
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:CYCN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners